Skip to content
HowShorted

Altimmune, Inc. short interest in 2024

In 2024, Altimmune, Inc.'s disclosed short interest ran from 19.84% of shares outstanding on 12 Jan 2024 to 33.31% on 31 Dec 2024, a change of +13.47 percentage points. The year's high was 33.54% on 13 Dec 2024 and its low 18.63% on 31 Jan 2024, averaging 29.20% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.09 days on 31 Oct 2024. Full history: Altimmune, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Altimmune, Inc. in 2024

2024 in figures

Start of year
19.84% (12 Jan 2024)
End of year
33.31% (31 Dec 2024)
Change
+13.47 pp
High
33.54% (13 Dec 2024)
Low
18.63% (31 Jan 2024)
Average
29.20%
Highest days to cover
13.09 (31 Oct 2024)
SEC filings marked
8

Every report in 2024

Altimmune, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202419.84%1.18
31 Jan 202418.63%1.82
15 Feb 202421.50%2.33
29 Feb 202420.13%1.38
15 Mar 202423.29%2.51
28 Mar 202425.01%4.1210-K filed, results (8-K)
15 Apr 202428.73%6.46
30 Apr 202431.46%7.41
15 May 202432.53%7.5810-Q filed, results (8-K)
31 May 202433.11%9.32
14 Jun 202432.64%9.53
28 Jun 202431.37%2.82
15 Jul 202431.88%7.14
31 Jul 202431.37%9.09
15 Aug 202430.53%8.7210-Q filed, results (8-K)
30 Aug 202430.96%9.82
13 Sep 202430.78%8.71
30 Sep 202431.51%9.45
15 Oct 202431.28%12.75
31 Oct 202432.27%13.09
15 Nov 202432.11%4.2910-Q filed, results (8-K)
29 Nov 202432.95%8.04
13 Dec 202433.54%6.10
31 Dec 202433.31%8.46

See also: Altimmune, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.